Yannick Romero on the changing landscape of national cancer control plans

The Lancet Oncology in conversation with

Player FM - Internet Radio Done Right

Lagt til four år siden

Innhold levert av The Lancet Group. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av The Lancet Group eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

In Her Ellement

1
Navigating Career Pivots and Grit with Milo’s Avni Patel Thompson 26:18

for 14 dager siden26:18

Spill senere

Lister

Lik

Likt

26:18

How do you know when it’s time to make your next big career move? With International Women’s Day around the corner, we are excited to feature Avni Patel Thompson, Founder and CEO of Milo. Avni is building technology that directly supports the often overlooked emotional and logistical labor that falls on parents—especially women. Milo is an AI assistant designed to help families manage that invisible load more efficiently. In this episode, Avni shares her journey from studying chemistry to holding leadership roles at global brands like Adidas and Starbucks, to launching her own ventures. She discusses how she approaches career transitions, the importance of unpleasant experiences, and why she’s focused on making everyday life easier for parents. [01:26] Avni's University Days and Early Career [04:36] Non-Linear Career Paths [05:16] Pursuing Steep Learning Curves [11:51] Entrepreneurship and Safety Nets [15:22] Lived Experiences and Milo [19:55] Avni’s In Her Ellement Moment [20:03] Reflections Links: Avni Patel Thompson on LinkedIn Suchi Srinivasan on LinkedIn Kamila Rakhimova on LinkedIn Ipsos report on the future of parenting About In Her Ellement: In Her Ellement highlights the women and allies leading the charge in digital, business, and technology innovation. Through engaging conversations, the podcast explores their journeys—celebrating successes and acknowledging the balance between work and family. Most importantly, it asks: when was the moment you realized you hadn’t just arrived—you were truly in your element? About The Hosts: Suchi Srinivasan is an expert in AI and digital transformation. Originally from India, her career includes roles at trailblazing organizations like Bell Labs and Microsoft. In 2011, she co-founded the Cleanweb Hackathon, a global initiative driving IT-powered climate solutions with over 10,000 members across 25+ countries. She also advises Women in Cloud, aiming to create $1B in economic opportunities for women entrepreneurs by 2030. Kamila Rakhimova is a fintech leader whose journey took her from Tajikistan to the U.S., where she built a career on her own terms. Leveraging her English proficiency and international relations expertise, she discovered the power of microfinance and moved to the U.S., eventually leading Amazon's Alexa Fund to support underrepresented founders. Subscribe to In Her Ellement on your podcast app of choice to hear meaningful conversations with women in digital, business, and technology.…

for ca. et år siden 24:40

MP3•Episoder hjem

Tell us what you thought about this episode

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

207 episoder

#Fitness #Medicine #Science #Biology #Podcasting Education #Lancet Groups #Cancer #Radiotherapy #Chemotherapy #MRNA

Yannick Romero on the changing landscape of national cancer control plans

The Lancet Oncology in conversation with

published for ca. et år siden

Del

MP3•Episoder hjem

Tell us what you thought about this episode

207 episoder

#Fitness #Medicine #Science #Biology #Podcasting Education #Lancet Groups #Cancer #Radiotherapy #Chemotherapy #MRNA

Alle episoder

1
Ariana Znaor on cancer surveillance in the Eastern Mediterranean region 20:03

for 13 dager siden20:03

20:03

Ariana Znaor (Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France) discusses her Review on cancer surveillance in the Eastern Mediterranean Region: a 10-year IARC-WHO EMRO collaboration. Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv…

1
Ian Tannock on Common Sense Oncology principles for phase 3 randomised clinical trials 18:03

for 6 weeks siden18:03

18:03

Professor Ian Tannock (Princess Margaret Cancer Centre and the University of Toronto, Toronto, Canada) discusses his Policy Review on Common Sense Oncology principles for the design, analysis and reporting of phase 3 randomised clinical trials. Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv…

1
Yannick Romero on the changing landscape of national cancer control plans 24:40

for 10 weeks siden24:40

24:40

Dr Yannick Romero (Union for International Cancer Control) discusses his Policy Review on the changing landscape of the national cancer control plans and his work with the international cancer control partnership. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00405-4/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv…

1
M Saiful Huq and Mostafa Aziz Sumon on the series Cancer Care in South Asian Association for Regional Cooperation (SAARC) Countries 22:15

for 15 weeks siden22:15

22:15

Professor M Saiful Huq (Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, USA) and Dr Mostafa Aziz Sumon (Radiation Oncology, Kurmitola General Hospital, Dhaka, Bangladesh) discuss their Series on Cancer Care in South Asian Association for Regional Cooperation (SAARC) Countries. Read the full Series: https://www.thelancet.com/series/cancer-care-in-saarc-countries?dgcid=buzzsprout_icw_podcast_generic_lanonc Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv…

1
Steven Horwitz on valemetostat for relapsed or refractory T-cell lymphoma 15:07

for 20 weeks siden15:07

15:07

Dr Steven Horwitz (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses a phase 1 study of valemetostat in relapsed or refractory non-Hodgkin lymphoma and a phase 2 study of valemetostat in relapsed or refractory peripheral T-cell lymphoma. Read the full Articles here: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00502-3/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00503-5/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv…

1
Zachary Zumsteg on early phase trial design for novel drug-radiotherapy combination 17:21

for 24 weeks siden17:21

17:21

Dr Zachary Zumsteg (Cedars-Sinai Medical Center, Los Angeles, CA, USA) discusses his Review on the challenges and opportunities for early phase clinical trials of novel drug-radiotherapy combinations. Read the full Article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00264-X/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv…

1
May Abdel-Wahab and Andrew Scott on The Lancet Oncology Commission on Radiotherapy and Theranostics 40:45

for 24 weeks siden40:45

40:45

May Abdel-Wahab (Division of Human Health, Department of Nuclear Science and Applications, International Atomic Energy Agency, Vienna, Austria) and Andrew Scott (Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia) discuss The Lancet Oncology Commission on Radiotherapy and Theranostics. Read the Commission: https://www.thelancet.com/commissions/radiotherapy-theranostics?dgcid=buzzsprout_icw_podcast_generic_lanonc Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv…

1
Kanwal Raghav on trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02) 13:22

for 29 weeks siden13:22

13:22

Dr Kanwal Raghav (Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA) discusses his Article entitled, ‘Trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a randomised, multicentre, phase 2 trial’. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00380-2/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv…

1
Emmy Boerrigter on dose selection of novel anticancer drugs 11:41

for 33 weeks siden11:41

11:41

Dr Emmy Boerrigter (Department of Pharmacy, Radboud University Medical Center, Netherlands) discusses her Review on dose selection of novel anticancer drugs: exposing the gap between selected and required doses. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00134-7?dgcid=buzzsprout_icw_podcast_generic_lanonc Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv…

1
Hisham Mehanna and Sue Yom on head and neck cancer consensus recommendations 36:56

for 38 weeks siden36:56

36:56

Dr Hisham Mehanna (University of Birmingham, Birmingham, UK) and Dr Sue Yom (University of California, San Francisco, San Francisco, CA, USA) discuss their four-paper Series on Head and Neck Cancer Consensus Recommendations in diagnosis and clinical trial endpoints. Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv…

1
Garth Strohbehn and Katie Lichter on the environmental impact of cancer treatment 24:08

for 42 weeks siden24:08

24:08

Dr Garth Strohbehn (Veteran Affairs Center for Clinical Management Research, Ann Arbor, Michigan, USA) and Dr Katie Lichter (University of California, San Francisco, USA) discuss their papers on the environmental impact of cancer treatments and the public harms resulting from it. Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv…

1
James Shultz, Ana Patricia Ortiz, and Leticia Nogueira on cancer and compounding disasters in the Caribbean 35:05

for 46 weeks siden35:05

35:05

Dr James Shultz, (University of Miami Miller School of Medicine, Miami, USA), Dr Ana Patricia Ortiz (University of Puerto Rico, and University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico), and Dr Leticia Nogueira (American Cancer Society, Georgia, USA) discuss their Personal View entitled, ‘Protecting Caribbean patients diagnosed with cancer from compounding disasters. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00071-8?dgcid=buzzsprout_icw_podcast_generic_lanonc Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv…

1
Bernardo Goulart on correlations of endpoints in lung cancer immunotherapy trials 11:22

for 49 weeks siden11:22

11:22

Dr Bernardo Goulart (US Food and Drug Administration) discusses his paper on correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00040-8/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv…

1
Maria Kyrgiou on innovations in gynaecological cancers and global disparities 25:42

for 1 year siden25:42

25:42

In a special episode on International Women's Day 2024, we speak with Dr Maria Kyrgiou (Imperial College London, London, UK) about her Essay on innovations and disparities in gynaecological cancer care. Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv…

1
Georgios Lyratzopoulos on the use of chemotherapy and radiotherapy in patients with eight common cancers 34:43

for 1 year siden34:43

34:43

Dr Georgios Lyratzopoulos (University College London, London, UK) discusses his two papers from the International Cancer Benchmarking Partnership on the use of chemotherapy or radiotherapy in eight common cancers in Norway, the UK, Canada, and Australia. Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv…

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.